Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab

• Published in: American journal of clinical dermatology Vol. 17; no. 6; pp. 691 - 699
• Main Authors: Armstrong, April W., Villanueva Quintero, Delfina Guadalupe, Echeverría, Cristina M., Gu, Yihua, Karunaratne, Mahinda, Reyes Servín, Ofelia
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.12.2016; Springer Nature B.V
• Subjects: Adalimumab - therapeutic use; Adult; Anti-Inflammatory Agents - therapeutic use; Dermatology; Double-Blind Method; Female; Humans; Male; Medicine; Medicine & Public Health; Middle Aged; Original; Original Research Article; Pharmacology/Toxicology; Pharmacotherapy; Psoriasis - drug therapy; Quality of Life; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome; Psoriasis; Adalimumab; Dermatology Life Quality Index; Dermatology Life Quality Index Score; Body Region

Background Psoriasis severity and treatment responsiveness vary by body region, which differentially impacts quality of life (QoL). Objective The objective of the study was to examine adalimumab efficacy by body region and regional response and QoL relationship. Methods Patients ( n  = 1212) with mo...